The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD

Fudan University450 enrolled

Overview

To determine the efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BID vs Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).

* This is a 12-week, multicentre,randomized,open-label,active-controlled, paralleled-group study. * Chinese patients aged ≥40 years with moderate-to-severe COPD are eligible for this study. 1. If satisfying the entry criteria, patients enter an 8 to 14 day run-in period,and replace previous bronchodilators with inhaled or nebulized Salbutamol. 2. Patients record daily severity ratings for daytime symptoms of shortness of breath, tiredness, activity limitation, frustration with symptoms, and night-time sleep symptoms on daily cards. 3. Each symptom is rated using 0-100 visual analog scal (VAS). For overall assessment of daytime symptoms, a combined symptom score is obtained by adding VAS scores for shortness of breath, tiredness, activity limitation, frustration with symptoms. 4. Patients are required to be symptomatic as demonstrated by a combined daytime symptom score of 120 on at least 4 of the 7 days prior to randomization.  1. Eligible patients will be randomized (1:1) to the following 2 treatments for 12 weeks. 1. Inhaled Salmeterol/Fluticasone propionate 50/500ug twice daily or inhaled IB/ALB 36/206ug QID. 2. Salbutamol will be provided for relief of symptoms on an "as required" basis during the whole 12 weeks. 2. A Follow-up visit will be conducted 2 weeks after completion of treatment/early withdrawal to assess for any adverse effects after discontinuing study treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

450

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Salmeterol/Fluticasone PropionateDRUG

Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks

Eligibility

Sex: ALLMin age: 40 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chinese male or female outpatients aged 40 to 79 years, inclusive * Patients with an established diagnosis of COPD, defined as GOLD guideline postbronchodilation FEV1/FVC ratio of \<70%, AND Postbronchodilation FEV1% predicted ranged from ≥25 to ≤70. * A cigarette smoking history of 10 pack-years * Use of oral theophylline, or any other inhaled medications other than LABA, LAMA, or ICS for≥30 days (e.g. SABA, SAMA) * Patients who are able to use Accuhaler device and relief medication * Patients willing to give informed consent to participate in the study and comply to study protocol * Eligible female on child-bearing potentia Exclusion Criteria: * Patients with concurrent respiratory disorders (e.g. asthma) other than COPD * Patients with a requirement for regular or long term oxygen therapy (\>12h/d) * Patients who used inhaled or oral steroids within 30 days of screening * Patients who had a respiratory tract infection requiring antibiotics within 14 days of screening * Patients with a moderate-to-severe COPD exacerbation within 30 days of screening * Patients with any significant medical condition or disease that would place patients at risk or interfere with the study evaluation. * Patients who used some inhibitory agents (e.g. b blockers) within 14 days of screening * Female patients who is pregnant or may be pregnant in the study duration

Locations (11)

Affiliated Hospital of Anhui Medical College

Hefei, Anhui, China

RECRUITING

Beijing Chaoyang Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

pre-broncholidator FEV1

Change from Baseline in pre-broncholidator FEV1 at 12 weeks

Time frame: at 12 weeks

Secondary Outcomes

post-broncholidator FEV1

Change from Baseline in post-broncholidator FEV1 at 12 weeks

Time frame: at 12 weeks

Morning PEF, inspiration capacity (IC) and Residual Volume (RV)

Change from Baseline in morning PEF, inspiration capacity (IC) and Residual Volume (RV)at 12 weeks

Time frame: at 12 weeks

Overall daytime symptom score, reliever medication use,SGRQ and BODY index

Change from Baseline in overall daytime symptom score, reliever medication use,SGRQ and BODY index at 12 weeks

Time frame: at 12 weeks

Percent of symptom-free nights, sleep symptoms, nighttime awakenings due to respiratory symptoms

Change from Baseline in percent of symptom-free nights, sleep symptoms, nighttime awakenings due to respiratory symptoms at 12 weeks

Time frame: at 12 weeks

Biomarkers: serum Clara cell 16 (CC-16) protein and serum surfactant protein D (SPD)

Change from Baseline in biomarkers: serum Clara cell 16 (CC-16) protein and serum surfactant protein D (SPD) at 12 weeks

Time frame: at 12 weeks

participants with adverse events and COPD exacerbations

Change from Baseline in number of participants with adverse events and COPD exacerbations at 12 weeks

Time frame: at 12 weeks

Central Contacts

Yutong Y GU, Doctor

CONTACT

8621-64041990 gu.yutong@zs-hospital.sh.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.